← Back to Companies

Amunix Pharmaceuticals

Biotechnology company that developed XTEN protein engineering and protease-activated prodrug technologies for oncology therapeutics. Acquired by Sanofi in 2021 for up to $1.225 billion.

Location
South San Francisco, California, USA
Founded
2007
Categories
biotech, oncology, protein-engineering, acquired

Notes

Amunix Pharmaceuticals was a biotechnology company that developed innovative protein engineering platforms for creating next-generation biologics. The company's proprietary XTEN technology enabled the extension of half-life and improvement of drug properties, while its Pro-XTEN platform created protease-activated prodrugs that activate specifically in the tumor microenvironment.

Acquired by Sanofi in August 2021 for $1 billion upfront plus up to $225 million in milestone payments. The acquisition provided Sanofi with Amunix's pipeline of masked T cell engagers and its XTEN/Pro-XTEN platforms.

Team

Additional Research Findings

  • In Bain Capital Life Sciences portfolio (pre-acquisition)
  • XTEN technology extends protein half-life through unstructured polypeptide fusion
  • Pro-XTEN creates masked/prodrug biologics activated by tumor proteases
  • Lead programs included masked T cell engagers for oncology
  • AMX-818 (HER2xCD3 T cell engager) advanced to clinical development
  • Acquisition by Sanofi for up to $1.225 billion (August 2021)
  • Technology now integrated into Sanofi oncology pipeline

Sources